EFFICACY AND SAFETY OF PAZOPANIB FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA: A SINGLE-INSTITUTION STUDY

Autor:	Tomoaki Terakawa, Ken-ichi Harada, Takuto Hara, Yuzo Nakano, Katsumi Shigemura, Yusuke Shiraishi, Junya Furukawa, Takeshi Ishimura, Nobuyuki Hinata, Yasuyoshi Okamura, Kohtaro Suzuki, Yukari Bando, Masato Fujisawa
Rok vydání:	2018
Předmět:	medicine.medical_specialty business.industry Urology medicine.disease Gastroenterology Pazopanib Stable Disease Renal cell carcinoma Internal medicine Vomiting Medicine Progression-free survival Single institution medicine.symptom business Adverse effect Risk criteria medicine.drug
Zdroj:	The Japanese Journal of Urology. 109:216-219
ISSN:	1884-7110 0021-5287
DOI:	10.5980/jpnjurol.109.216
Popis:	To investigate the efficacy and safety of first-line Pazopanib advanced or metastatic renal cell carcinoma (RCC): a single-institution study. (Patients and methods) We gathered 23 RCC patients treated between April 2014 and February 2018 in our institution and examined the treatments outcome and adverse events (AEs). (Results) Their risk criteria were categorized as follows: Favorable (n=2), Intermediate (n=12) and Poor (n=9) by International mRCC Database Consortion (IMDC). Median progression free survival (PFS) was 8.6 months and median overall survival (OS) was unreached. Best response (BR) of Pazopanib was partial response (PR): n=10, 50.0%, stable disease (SD): n=8, 40.0% and progression disease (PD): n=2, 10.0% (Three patients had no evaluable data,). AEs of Grade3 had liver dysfunction (n=3), thrombocytopenia (n=2), hand-foot syndrome (n=1), vomiting (n=1) and bowel bleeding (n=1). (Conclusion) The fist-line pazopanib demonstrated good clinical benefit with well-tolerance.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781a4f01db7ae0e95d2faf3374960638 https://doi.org/10.5980/jpnjurol.109.216 Zobrazit plný text záznamu